Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of 3D-229 in healthy subjects
NCT04941313Phase 1Completed
- Sponsor
- 3D Medicines Inc.
- Start
- Jul 2021
- Primary completion
- Nov 2021
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of batiraxcept in ovarian cancer, renal cell carcinoma (RCC) and solid tumor (4 arms), sponsored by 3D Medicines Inc. Primary endpoint: Safety and tolerability of 3D229 up to 7 weeks. Started Jul 2021; status: completed.
02
Drugs
batiraxcept
03
Conditions
ovarian cancerrenal cell carcinoma (RCC)solid tumor
Beyond the preview
Go deeper on NCT04941313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04941313.